1. ESMOupdate 2012, Gastrointestinal Cancers

Dr. med. Sabina Schacher und Dr. med. Daniel Helbling besprechen die wichtigsten, klinisch relevanten Studien im Bereich Gastrointestinal Cancers, die am diesjährigen ESMO (European Society for Medical Onocology) Meeting in Wien präsentiert wurden.

Diskutierte Studien:
LBA18: Phase 3 CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC): Overall survival update; E. van Cutsem et al

LBA17: A randomized phase III study evaluating the continuation of bevacizumab (BV) beyond progression in metastatic colorectal cancer (mCRC) patients (pts) who received BV as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord; G. Masi et al

Leave a Reply

Your email address will not be published. Required fields are marked *